This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Digital Health and Digital Therapeutics: Where are we heading and why?
Webinars, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
Drug, Device, Digital: Reimagined Healthcare
Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Brand Differentiation
Nasal Drug Delivery Challenges and Trends Ahead
Publications, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations, Brand Differentiation
Aptar Pharma discusses digital therapeutics for chronic conditions
Publications, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations, Brand Differentiation
